Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Omvoh正在VIVID-2研究中进行评估，这是一项正在进行的开放标签扩展（OLE）研究，旨在评估Omvoh对中度至重度活动性克罗恩病患者的三年疗效和安全性。

Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...

Lilly has also submitted marketing applications for Omvoh in Crohn's disease around the globe, including in the European Union and Japan. Additional global regulatory submissions are planned.

智通财经APP获悉，礼来(LLY.US)周一公布的研究结果显示，Mirikizumab(商品名Omvoh)对溃疡性结肠炎(UC)和克罗恩病具有长期疗效。该制药商声称，根据两项 ...

Eli Lilly won Food and Drug Administration approval to sell its Omvoh medicine for adults with Crohn’s disease, adding to the potential market for a drug first approved in 2023.

礼来（LLY.US）周一公布的研究结果显示，Mirikizumab（商品名Omvoh）对溃疡性结肠炎（UC）和克罗恩病具有长期疗效。 该制药商声称，根据两项针对中度 ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn ...

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh ...

Lilly has also submitted marketing applications for Omvoh in Crohn's disease around the globe, including in the European Union and Japan. Additional global regulatory submissions are planned.